TuHURA Biosciences, Inc./NV
HURA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.04
KIRA · Stoqly’s AI analyst, in plain words
- TuHURA Biosciences, Inc./NV had $0.0M of revenue in fiscal 2025.
- TuHURA Biosciences, Inc./NV lost $30.1M in fiscal 2025.
- Free cash flow was −$27.7M in fiscal 2025, — of revenue.
Market cap
$130M
P/E
—
Revenue
$0.0M
Net income
−$30.1M
Free cash flow
−$27.7M
Operating margin
—
TuHURA Biosciences, Inc./NV in 30 seconds · fiscal 2025
Does it make a profit?
−$30.1M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What TuHURA Biosciences, Inc./NV does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- TuHURA Biosciences, Inc./NV
- CIK
- 0001498382
TuHURA Biosciences, Inc./NV · HURA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY19 | FY20 | FY21 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | — | $0.0M |
| Net income | −$9.1M | −$38.3M | −$22.7M | −$14.6M | −$30.1M |
| Diluted EPS | — | — | — | — | −$0.63 |
| Cash | |||||
| Cash from operations | −$7.9M | −$18.9M | −$20.4M | −$11.9M | −$27.6M |
| Capital expenditure | — | — | $0.2M | — | $0.1M |
| Free cash flow | — | — | −$20.6M | — | −$27.7M |
| Debt and strength | |||||
| Cash and short-term investments | $2.4M | $10.5M | $11.8M | $12.7M | $3.6M |
| Shareholders' equity | $0.3M | $10.6M | $11.8M | $14.6M | $20.9M |
| Current ratio | 1.1x | 4.2x | 3.3x | 3.7x | 0.8x |
| Returns and quality | |||||
| Return on equity | −818.1% | −706.3% | −202.5% | −100.4% | −169.2% |
| Return on tangible equity | −3,503.1% | −392.3% | −213.1% | −102.9% | −294.9% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
TuHURA Biosciences, Inc./NV · HURA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.04 a share, the company is worth $130M.
Source: SEC EDGAR XBRL filings (CIK 0001498382). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.